These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17434108)

  • 21. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
    Lawton CA; DeSilvio M; Lee WR; Gomella L; Grignon D; Gillin M; Morton G; Pisansky T; Sandler H
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):39-47. PubMed ID: 17084551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostate cancer].
    Vieillot S; Fenoglietto P; Aillères N; Hay MH; Dubois JB; Azria D
    Cancer Radiother; 2010 Nov; 14 Suppl 1():S161-73. PubMed ID: 21129660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High intensity focused ultrasound (HIFU).
    Barkin J
    Can J Urol; 2011 Apr; 18(2):5634-43. PubMed ID: 21504653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate brachytherapy training with simulated ultrasound and fluoroscopy images.
    Goksel O; Sapchuk K; Morris WJ; Salcudean SE
    IEEE Trans Biomed Eng; 2013 Apr; 60(4):1002-12. PubMed ID: 23047861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applicability and dosimetric impact of ultrasound-based preplanning in high-dose-rate brachytherapy of prostate cancer.
    Aebersold DM; Isaak B; Thalmann G; Behrensmeier F; Kolotas C; Kranzbühler H; Mini R; Greiner RH
    Strahlenther Onkol; 2004 Jun; 180(6):351-7. PubMed ID: 15175869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current role of imaging for prostate brachytherapy.
    Carey B; Swift S
    Cancer Imaging; 2007 Feb; 7(1):27-33. PubMed ID: 17339141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brachytherapy in patients with small prostate glands.
    Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
    Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brachytherapy for clinically localized prostate cancer: optimal patient selection.
    Kollmeier MA; Zelefsky MJ
    Arch Esp Urol; 2011 Oct; 64(8):847-57. PubMed ID: 22052766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
    Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis.
    Coen JJ; Zietman AL; Rossi CJ; Grocela JA; Efstathiou JA; Yan Y; Shipley WU
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e25-31. PubMed ID: 21470787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Martinez AA; Gonzalez J; Ye H; Ghilezan M; Shetty S; Kernen K; Gustafson G; Krauss D; Vicini F; Kestin L
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):363-70. PubMed ID: 21195875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transrectal ultrasound-guided interstitial radiation therapy for localized prostate cancer.
    Brosman SA; Tokita K
    Prog Clin Biol Res; 1991; 370():291-300. PubMed ID: 1924462
    [No Abstract]   [Full Text] [Related]  

  • 38. Anatomy-related and transrectal sonography-guided interstitial high-dose rate brachytherapy combined with elective irradiation of the pelvic lymphatics for localized prostate cancer: the Kiel experience.
    Galalae R; Kovács G; Loch T; Bertermann H; Kohr P; Oldörp A; Kimmig B
    Front Radiat Ther Oncol; 2002; 36():183-90. PubMed ID: 11842751
    [No Abstract]   [Full Text] [Related]  

  • 39. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):648-53. PubMed ID: 15380602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.